Harnessing innate power: Targeting the root causes of inflammation and fibrosis

Our approach is to target upstream innate immune amplifiers that underpin persistent inflammatory and fibrotic responses to restore tissue homeostasis and disrupt disease progression.

At Calluna Pharma we are developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential applicability across a diverse array of medical conditions. Calluna Pharma is a clinical stage company driven by a commitment to improve patient outcomes in areas where existing treatments are sub-optimal.

We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

We have four promising therapies in the pipeline, with preclinical proof of concept data.

CAL101

Explores targeted pleiotropism, offering a novel approach to fibrosis and inflammation treatment.

CAL102

Developed to treat myocardial infarction induced reperfusion injury via the neutralisation of oxidised phospholipids (OxPL) in the myocardium.

CAL103

Explores targeted pleiotropism across a range of inflammatory and fibrotic conditions.

CAL104

Leveraging the benefits of neutralising both OxPL and S100A4 in inflammation and fibrosis settings.

Our Pipeline

We bring together a mix of skills and backgrounds, from various academic institutions to different roles in biotech and large pharma companies. Our collective experience helps us navigate the complexities of drug discovery and development, merging strategic thinking with practical know-how and a strong commitment to effective clinical execution.

John Montana
John Montana PhD

CEO

John’s 30 years of diverse R&D experience shapes Calluna Pharma’s innovative edge, blending drug discovery acumen with strong leadership.

Jonas Hallen
Jonas Hallén MD PhD

CMO and Founder

As a co-founder and passionate drug developer, Jonas strongly believes in the power of science to make a meaningful impact on patients’ lives.

Louise Kooij
Louise Kooij

CFO

With a career spanning pharma and biotech, Louise provides Calluna Pharma with financial leadership, fostering strategic growth and stability.

Man looking over valley

Our unique therapeutic solutions, targeting sentinel modulators and key self-amplifying alarm signals of the immune system, present an exciting investment opportunity. Noted industry investor Forbion already recognizes Calluna Pharma’s potential and has made a strategic investment, underscoring our credibility and commercial promise.

A partnership with Calluna Pharma brings more than just the potential for financial gains. It’s an opportunity to contribute to improving patient outcomes and elevating therapeutic standards. The combination of our scientific excellence, discovery expertise, and accomplished management team, alongside our robust clinical plans could add considerable credibility to your investment portfolio.

Keep up to date with our recent breakthroughs and partnerships as we endeavour to identify novel life changing treatments for a range of inflammatory and fibrotic diseases.

News Placeholder
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.

Read more
More news coming soon

More news coming soon

"*" indicates required fields

Stay informed on developments*

We would like to keep you up to date with our latest insights and breakthroughs – would you like to be part of our mailing list? We will not pass your details onto any third parties.

informed*

Calluna Pharma needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.